Attachment
Gates Package, p.1185 · gates:exh:00579
Page text: p.1185 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
about 10 times more lethal than flu, vaccines and antivirals could cut that number by half or
more. Communities will still see occasional outbreaks, but new drugs will be available that could
take care of most cases and hospitals will be able to handle the rest. Your individual risk level
will be low enough that you won't need to factor it into your decision-making as much. It won't
be primary when deciding whether to work from the office or let your kids go to their soccer
game or watch a movie in a theater. In a couple years, my hope is that the only time you will
really have to think about the virus is when you get your joint COVID and flu vaccine every fall.
Now that we're starting to move toward the end of this pandemic, I've been spending a lot of
time thinking about what went right and what went wrong over the last two years. We can
learn important lessons from the world's COVID-19 response that will make us better prepared
next time.
Even though the pandemic has dragged on longer than anticipated, a lot has gone well. To
start, the progress we've made on vaccines is remarkable. The world has never made and
distributed a vaccine for a disease faster than it did for COVID-19. The fact that we had one--let
alone multiple!--vaccines during the first year of the pandemic is miraculous. That success is a
tribute to how many candidates the world had in the pipeline. Vaccine development relies on a
little bit of luck, and we hedged our bets by trying so many different approaches.
I think mRNA vaccines will ultimately be seen as the most consequential breakthrough
of the pandemic. Proving that mRNA works as a vaccine platform has been a massive
gamechanger--not just for this pandemic, but for the next one too. Now that mRNA is well
established, we'll be able to develop safe and effective vaccines super-fast in the future.
We also learned a lot about nonpharmaceutical interventions (or NPIs) that will inform
disease response moving forward. NPIs include things like mask mandates, quarantine
procedures, and travel restrictions. The last two years have given us the opportunity to see
how effective different strategies are against a respiratory disease like COVID. Next time, the
world will be ready to deploy cheap and easy tools like masks much quicker, and governments
will have a greater understanding of when and how to deploy more burdensome strategies
like lockdowns.